Collegium Pharmaceutical (COLL) Convertible Debt (2020 - 2026)

Collegium Pharmaceutical's Convertible Debt history runs 7 years deep, the most recent figure standing at $238.5 million for Q1 2026.

• In Q1 2026, Convertible Debt changed 0.44% year-over-year to $238.5 million; the TTM figure through Mar 2026 stood at $238.5 million (changed 0.44% YoY), while the FY2025 annual figure was $238.2 million, changed 0.44% from the prior year.
• Convertible Debt was $238.5 million for Q1 2026 at Collegium Pharmaceutical, roughly flat from $238.2 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $262.4 million in Q1 2024 to a low of $26.4 million in Q1 2022.
• Historically, Convertible Debt has averaged $215.2 million across 5 years, with a median of $237.7 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Convertible Debt plunged 81.08% in 2022, then soared 891.35% in 2023.
• A 5-year view of Convertible Debt shows it stood at $140.9 million in 2022, then soared by 86.07% to $262.1 million in 2023, then dropped by 9.52% to $237.2 million in 2024, then rose by 0.44% to $238.2 million in 2025, then gained by 0.11% to $238.5 million in 2026.
• The last three Convertible Debt figures came in at $238.5 million (Q1 2026), $238.2 million (Q4 2025), and $238.0 million (Q3 2025), per Business Quant data.